TY  - JOUR
AU  - Taïeb, Julien
AU  - Aranda, Enrique
AU  - Raouf, Sherif
AU  - Dunn, Helen
AU  - Arnold, Dirk
PY  - 2020
DO  - 10.1016/j.clcc.2020.10.005
UR  - http://hdl.handle.net/10668/16675
T2  - Clinical colorectal cancer
AB  - Biosimilars - biological medicines highly similar to a licensed reference product (RP) - can mitigate the risk of drug shortages by providing treatment alternatives and, with their lower costs, increase patient access to medication and reduce health...
LA  - en
PB  - Elsevier
KW  - Drug approval
KW  - Extrapolation
KW  - Gastrointestinal cancer
KW  - MVASI
KW  - Sensitive population
KW  - Antineoplastic agents, immunological
KW  - Bevacizumab
KW  - Biosimilar pharmaceuticals
KW  - Colorectal neoplasms
KW  - Drug approval
KW  - Equivalence trials as topic
KW  - Humans
KW  - Neoplasm staging
KW  - Progression-free survival
TI  - Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
TY  - research article
VL  - 20
ER  -